Direct Load Capture Cap Collection Kit

No specimen transfer.

Placeholder image

    Overview

    Documents

    Training

    Transform specimen processing with the only nasopharyngeal (NP) swab that loads directly for COVID testing.

    No specimen transfer. Expedite your SARS-CoV-2* workflow with a collection device that loads directly on the Panther® system.  The Direct Load Capture Cap Collection Kit is authorized for use with the Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays. 

    Deliver Results Sooner

    Uncap & Load

    • Directly load alongside specimen types for other assays with true random and continuous access.
    • Non-hazardous lysis buffer reduces risk by inactivating common respiratory viruses, minimizing biosafety needs.

    Traditional 8-Step Respiratory Specimen Workflow

    1

    Uncap Collection Tube

     

    2

    Uncap Transfer Tube

     

    3

    Transfer Primary Specimen

     

    4

    Recap Transfer Tube

     

    5

    Recap Collection Tube

     

    6

    Mix Transfer Tube

     

    7

    Uncap Transfer Tube

     

    8

    Load onto System

     

    Reduce Labor/Costs/Risk with Fewer Steps

    • Eliminate manual specimen transfer steps.
    • Reduce potential for human error.
    • Remove costs for additional consumables.
    • FLOQSwab® for NP and mid-turbinate collection.
    • Inactivates common respiratory viruses.
    • Guanidine free, non-toxic media.
    FLOQSwab® is a registered trademark of COPAN Diagnostics
    * The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays have not been FDA cleared or approved; These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima SARS-CoV-2 assay has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A and Flu B and not for any other viruses or pathogens. The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. 

    Safety Data Sheets

    Package Inserts